RU2311172C2 - Твердая лекарственная композиция с производным пиперазиномочевины - Google Patents

Твердая лекарственная композиция с производным пиперазиномочевины

Info

Publication number
RU2311172C2
RU2311172C2 RU2004115328/15A RU2004115328A RU2311172C2 RU 2311172 C2 RU2311172 C2 RU 2311172C2 RU 2004115328/15 A RU2004115328/15 A RU 2004115328/15A RU 2004115328 A RU2004115328 A RU 2004115328A RU 2311172 C2 RU2311172 C2 RU 2311172C2
Authority
RU
Russia
Prior art keywords
methyl
piperazine
composition according
drug composition
solid drug
Prior art date
Application number
RU2004115328/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2004115328A (ru
Inventor
Хейко КРАНЦ (DE)
Хейко КРАНЦ
Кристоф ФОЛЬКЕЛЬ (DE)
Кристоф ФОЛЬКЕЛЬ
Ральф ЛИПП (DE)
Ральф Липп
Иоганнес ТАКК (DE)
Иоганнес ТАКК
Герберт ВИЗИНГЕР (DE)
Герберт ВИЗИНГЕР
Original Assignee
Шеринг Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шеринг Акциенгезельшафт filed Critical Шеринг Акциенгезельшафт
Publication of RU2004115328A publication Critical patent/RU2004115328A/ru
Application granted granted Critical
Publication of RU2311172C2 publication Critical patent/RU2311172C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2004115328/15A 2001-10-18 2002-10-07 Твердая лекарственная композиция с производным пиперазиномочевины RU2311172C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10152351.3 2001-10-18
DE10152351A DE10152351B4 (de) 2001-10-18 2001-10-18 Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat

Publications (2)

Publication Number Publication Date
RU2004115328A RU2004115328A (ru) 2005-06-10
RU2311172C2 true RU2311172C2 (ru) 2007-11-27

Family

ID=7703496

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004115328/15A RU2311172C2 (ru) 2001-10-18 2002-10-07 Твердая лекарственная композиция с производным пиперазиномочевины

Country Status (23)

Country Link
EP (1) EP1435917A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005506365A (cg-RX-API-DMAC7.html)
KR (1) KR20040047920A (cg-RX-API-DMAC7.html)
CN (1) CN1571660A (cg-RX-API-DMAC7.html)
AR (1) AR037111A1 (cg-RX-API-DMAC7.html)
AU (1) AU2002333896B2 (cg-RX-API-DMAC7.html)
BR (1) BR0213340A (cg-RX-API-DMAC7.html)
CA (1) CA2463951A1 (cg-RX-API-DMAC7.html)
CO (1) CO5580740A2 (cg-RX-API-DMAC7.html)
DE (1) DE10152351B4 (cg-RX-API-DMAC7.html)
EC (1) ECSP045108A (cg-RX-API-DMAC7.html)
HR (1) HRP20040435A2 (cg-RX-API-DMAC7.html)
IL (1) IL161166A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04003522A (cg-RX-API-DMAC7.html)
NO (1) NO20042022L (cg-RX-API-DMAC7.html)
NZ (1) NZ532287A (cg-RX-API-DMAC7.html)
PE (1) PE20030472A1 (cg-RX-API-DMAC7.html)
PL (1) PL367987A1 (cg-RX-API-DMAC7.html)
RS (1) RS32204A (cg-RX-API-DMAC7.html)
RU (1) RU2311172C2 (cg-RX-API-DMAC7.html)
UY (1) UY27500A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003035037A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200403781B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2729223C1 (ru) * 2020-05-13 2020-08-05 Мераб Георгиевич Чикобава Дозированная форма для амплификации нуклеиновых кислот

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3909056B2 (ja) 2001-06-27 2007-04-25 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
EP1749519A1 (de) * 2005-08-05 2007-02-07 Schering Aktiengesellschaft Arzneiform mit Retardtierter pH-unabhängiger Wirkstofffreisetzung für Wirkstoffe mit starker pH-abhängiger Löslichkeit
AU2007242077B2 (en) * 2006-04-26 2013-11-14 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
KR101654582B1 (ko) 2016-05-12 2016-09-06 그린로드(주) 원뿔형 부유 고분자 필터, 및 그의 제조장치 및 제조방법, 및 그를 포함하는 수처리 필터

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2085190C1 (ru) * 1990-04-17 1997-07-27 Еуранд Интернэшнл С.П.А. Твердая лекарственная форма для орального введения фармацевтически активных веществ, имеющих неблагоприятные органолептические свойства
WO1998034607A1 (en) * 1997-02-05 1998-08-13 F. Hoffmann-La Roche Ag Tetrahydrolipstatin containing compositions
WO1998056771A2 (en) * 1997-06-12 1998-12-17 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
RU2126013C1 (ru) * 1990-11-12 1999-02-10 Лаборатуар Терамекс С.А. Микрокристаллы, способ получения микрокристаллов, фармацевтическая композиция
RU2142793C1 (ru) * 1995-12-19 1999-12-20 Абботт Лаборэтриз Твердая фармацевтическая композиция с регулируемым высвобождением лекарственного средства

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE337307T1 (de) * 1998-02-05 2006-09-15 Pfizer Prod Inc Neue dihydroxyhexansäurederivate
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2085190C1 (ru) * 1990-04-17 1997-07-27 Еуранд Интернэшнл С.П.А. Твердая лекарственная форма для орального введения фармацевтически активных веществ, имеющих неблагоприятные органолептические свойства
RU2126013C1 (ru) * 1990-11-12 1999-02-10 Лаборатуар Терамекс С.А. Микрокристаллы, способ получения микрокристаллов, фармацевтическая композиция
RU2142793C1 (ru) * 1995-12-19 1999-12-20 Абботт Лаборэтриз Твердая фармацевтическая композиция с регулируемым высвобождением лекарственного средства
WO1998034607A1 (en) * 1997-02-05 1998-08-13 F. Hoffmann-La Roche Ag Tetrahydrolipstatin containing compositions
WO1998056771A2 (en) * 1997-06-12 1998-12-17 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
STREUBEL A. et al. pH-independent release of a weakly basic drug from water-insoluble and - soluble matrix tablets. - J Control Release, 2000 Jun 15. *
БОЧКОЙ Н.П., НАСОНОВА В.А. и др. Справочник врача общей практики. / Под ред. Н.Р. Палеева. - М.: ЭКСМО-Пресс, 2001. - В 2х томах. LIANG M. et al. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem. 2000 Jun 23; 275(25): 19000-8, реферат. *
ЧУЕШОВ В.И и др. Промышленная технология лекарств. Учебник в 2-х томах. Том 2. / Под ред. В.И. Чуешова. - X.: Основа. 1999. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2729223C1 (ru) * 2020-05-13 2020-08-05 Мераб Георгиевич Чикобава Дозированная форма для амплификации нуклеиновых кислот

Also Published As

Publication number Publication date
DE10152351B4 (de) 2005-09-22
CN1571660A (zh) 2005-01-26
MXPA04003522A (es) 2004-07-23
AU2002333896B2 (en) 2007-07-26
NO20042022L (no) 2004-05-14
AR037111A1 (es) 2004-10-20
PE20030472A1 (es) 2003-06-16
PL367987A1 (en) 2005-03-21
AU2002333896A2 (en) 2003-05-06
RU2004115328A (ru) 2005-06-10
EP1435917A1 (de) 2004-07-14
CA2463951A1 (en) 2003-05-01
HRP20040435A2 (en) 2005-06-30
BR0213340A (pt) 2004-10-05
JP2005506365A (ja) 2005-03-03
DE10152351A1 (de) 2003-05-08
WO2003035037A1 (de) 2003-05-01
KR20040047920A (ko) 2004-06-05
UY27500A1 (es) 2003-06-30
NZ532287A (en) 2007-04-27
RS32204A (sr) 2006-10-27
CO5580740A2 (es) 2005-11-30
IL161166A0 (en) 2004-08-31
ECSP045108A (es) 2004-06-28
ZA200403781B (en) 2004-11-29

Similar Documents

Publication Publication Date Title
US11096920B2 (en) Low-dose doxepin formulations and methods of making and using the same
US8545884B2 (en) Solid pharmaceutical formulations comprising BIBW 2992
RS59672B1 (sr) Čvrsti dozni oblici palbocikliba
JPH0251402B2 (cg-RX-API-DMAC7.html)
HK1205683A1 (en) Pharmaceutical formulation having improved stability
US7538094B2 (en) Composition containing ribavirin and use thereof
WO1997033571A1 (fr) Preparation d'ecadotril a microdispersion et liberation rapides
DE10152351B4 (de) Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
TWI745598B (zh) 非布司他控釋組合物及其製備方法
WO2005082329A2 (en) Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide
US20030087913A1 (en) Solid pharmaceutical agent formulation for a piperazine urea derivative
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
JP2015516971A (ja) ざ瘡の処置方法
WO2025265110A1 (en) Oral pharmaceutical compositions comprising a naphthyridine compound

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20081008